Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Blue Trust Inc.

Blue Trust Inc. decreased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 61.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,667 shares of the company’s stock after selling 8,952 shares during the period. Blue Trust Inc.’s holdings in Teva Pharmaceutical Industries were worth $125,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. AustralianSuper Pty Ltd lifted its holdings in Teva Pharmaceutical Industries by 16.8% in the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock valued at $203,268,000 after acquiring an additional 1,329,319 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Teva Pharmaceutical Industries by 21.8% during the fourth quarter. V Square Quantitative Management LLC now owns 19,802 shares of the company’s stock valued at $439,000 after purchasing an additional 3,549 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Teva Pharmaceutical Industries by 9.4% during the fourth quarter. Vontobel Holding Ltd. now owns 687,261 shares of the company’s stock valued at $15,147,000 after purchasing an additional 58,772 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after purchasing an additional 58,413 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $104,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 1.5 %

Shares of Teva Pharmaceutical Industries stock opened at $16.75 on Friday. The stock has a 50-day moving average price of $19.92 and a 200 day moving average price of $18.48. The company has a market cap of $18.97 billion, a P/E ratio of -11.55, a P/E/G ratio of 1.39 and a beta of 0.71. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 1 year low of $12.51 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts expect that Teva Pharmaceutical Industries Limited will post 2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares in the company, valued at $15,296,950. This represents a 29.15 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent research reports. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. Finally, Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.